Boundless Bio, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
BOLD$2.45-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
(in thousands, except par value data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $26,587 | $23,706 |
| Short-term investments | 125,527 | 97,046 |
| Prepaid expenses and other current assets | 2,276 | 3,452 |
| Total current assets | 154,390 | 124,204 |
| Property and equipment, net | 4,321 | 2,573 |
| Right-of-use asset, net | 47,039 | 2,002 |
| Restricted cash | 560 | 560 |
| Other assets | 99 | 555 |
| Total assets | $206,409 | $129,894 |
| Liabilities, convertible preferred stock, and stockholders’ equity/ (deficit) | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $5,354 | $4,266 |
| Accrued compensation | 2,781 | 2,898 |
| Lease liabilities, current portion | — | 2,195 |
| Total current liabilities | 8,135 | 9,359 |
| Lease liabilities, non-current | 47,632 | — |
| Total liabilities | 55,767 | 9,359 |
| Commitments and contingencies (Note 8) | ||
| Convertible preferred stock, $0.0001 par value; no shares authorized, issued, or outstanding as of December 31, 2024; 287,447 shares authorized, issued, and outstanding as of December 31, 2023 liquidation preference of $252.1 million as of December 31, 2023 | — | 247,617 |
| Stockholders’ equity/ (deficit): | ||
| Preferred stock, $0.0001 par value; 70,000 shares authorized and no shares issued and outstanding as of December 31, 2024; no shares authorized and no shares issued and outstanding as of December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 700,000 shares authorized, 22,300 shares issued and outstanding as of December 31, 2024; 402,600 shares authorized, 1,248 shares issued and outstanding as of December 31, 2023 | 2 | — |
| Additional paid-in-capital | 351,991 | 8,987 |
| Accumulated other comprehensive income | 121 | 40 |
| Accumulated deficit | (201,472) | (136,109) |
| Total stockholders’ equity/ (deficit) | 150,642 | (127,082) |
| Total liabilities, convertible preferred stock, and stockholders’ equity/ (deficit) | $206,409 | $129,894 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.